This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Systemic Lupus Erythematous SLE Drugs Market

Systemic Lupus Erythematosus (SLE) Drugs Market By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppresants, and Biologics), Route of Administration (Oral, Intravenous, and Subcutaneous) & Region - Forecast 2022-2032

Market Insights on Systemic Lupus Erythematous SLE Drugs covering sales outlook, demand forecast & up-to-date key trends

Systemic Lupus Erythematous SLE Drugs Market Overview

The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Bn in 2020, to reach a valuation of US$ 329.18 Bn by 2032.

The systemic lupus erythematosus (SLE) drugs market is anticipated to show promising growth prospects owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Attributes

Details

Systemic Lupus Erythematosus (SLE) Drugs Market Value (2020)

US$ 183.3 Bn

Systemic Lupus Erythematosus (SLE) Drugs Market (2032)

US$ 329.18 Bn

CAGR (2022-2032)

5%

Sales of systemic lupus erythematosus (SLE) drugs is expected to rise with the introduction of novel biological therapies in the development pipeline. In addition to this, demand for systemic lupus erythematosus (SLE) drugs is rising due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE).

This factor is anticipated to significantly influence the systemic lupus erythematosus (SLE) drugs market, as over 50% of SLE patients have lupus nephritis. 

Some new potential medications in Phase III studies are also projected to contribute to the growth of the systemic lupus erythematosus (SLE) drugs market share.

Some of the key systemic lupus erythematosus (SLE) drugs trends promoting the demand for systemic lupus erythematosus (SLE) drugs market include clinicians only administering biologics when two or more non-biologic immunosuppressants have failed to ameliorate a patient's disease activity.

Several nations have developed payment schemes based on these criteria, which greatly boosted the sales of systemic lupus erythematosus (SLE) drugs. 

In developed nations, demand for systemic lupus erythematosus (SLE) drugs is higher due to stronger healthcare infrastructure and coverage availability. In underdeveloped regions, high costs and a lack of government-funded coverage limit access to biologics.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Key Contributors to the Systemic Lupus Erythematosus (SLE) Drugs Market Share?

The global market for systemic lupus erythematosus (SLE) drugs is expected to expand due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE). The development of newer SLE medicines increased availability of biosimilar pharmaceuticals, and increased support for developing research areas for new drug molecules are increasing the sales of systemic lupus erythematosus (SLE) drugs and propelling the global systemic lupus erythematosus (SLE) drugs market forward. 

Increased awareness of illness diagnosis and treatment and constant research and development procedures for innovative therapeutic molecules are major drivers of the global systemic lupus erythematosus (SLE) drugs. Furthermore, the safety and quality of systemic lupus erythematous controlling therapy may provide a hurdle to the sales of systemic lupus erythematosus (SLE) drugs. 

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Region holds the Highest Growth Potential in the Systemic Lupus Erythematosus (SLE) Drugs Market?

Global systemic lupus erythematosus (SLE) drugs market growth is fast in the North American region and is estimated to project remarkable CAGR growth throughout the forecast period.

In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans, according to the Centers for Disease Control and Prevention (CDC). It is anticipated that this factor will boost the demand for systemic lupus erythematosus (SLE) drugs in the region.

The second-largest and fastest-growing systemic lupus erythematosus (SLE) drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double-digit CAGR due to the higher prevalence of SLE in Europe. According to the Lupus Journal article, among the European countries, Sweden, Iceland, and Spain recorded the highest sales of systemic lupus erythematosus (SLE) drugs.

This is expected to be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy, Spain, the UK and Japan. Benlysta will lead sales of systemic lupus erythematosus (SLE) drugs in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. 

Who are the Key Players in the Systemic Lupus Erythematosus (SLE) Drugs Market?

The key players in the global systemic lupus erythematous drugs market are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

Recent Developments

  • Hydroxychloroquine, the last drug, was approved by the FDA in 1955 for SLE treatment. 
  • Recently, a drug called belimumab was approved by FDA after 50 years long gap specifically for SLE, on March 9, 2011. It is the first-ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc. 
  • In collaboration with GlaxoSmithKline, Benlysta is anticipated to lead systemic lupus erythematosus (SLE) drugs market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. 
  • NSAIDs such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE.

Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth rate

CAGR of 5% from 2022 to 2032

Base year for estimation

2021

Historical data

2015 - 2020

Forecast period

2022 - 2032

Quantitative units

Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032

Report coverage

Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,

Segments covered

Drug Classes, Route of Administration, region

Regional scope

North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand

Country scope

U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa

Key companies profiled

Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs.

Frequently Asked Questions

The systemic lupus erythematous (SLE) drugs market is likely to register a CAGR of 5% during the forecast period (2022-2032).

Key players holding substantial systemic lupus erythematous (SLE) drugs market share include Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

As per the analysis, the systemic lupus erythematous (SLE) drugs market is likely to be US$ 329 Bn by 2032.

Demand for systemic lupus erythematous (SLE) drugs is likely to rise owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Systemic Lupus Erythematous SLE Drugs Market